The global prevalence of diabetes mellitus (DM) has led to widespread multi-system
damage, especially in cardiovascular and renal functions, heightening morbidity and …

Obesity presents a significant health challenge, affecting 41% of adults and 19.7% of
children in the United States. One of the associated health challenges of obesity is chronic …

Atherosclerotic cardiovascular disease is a chronic condition that often copresents with type
2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin …

Heart failure with preserved ejection fraction (HFpEF) is posing a significant medical
challenge due to its growing prevalence, high hospitalization rates and limited response to …

Introduction Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in
the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) …

Individuals with diabetes often have chronic inflammation and high levels of inflammatory
cytokines, leading to insulin resistance and complications. Anti-inflammatory agents are …

Diabetes is a global disease that can lead to a range of complications. Currently, the
treatment of type 2 diabetes focuses on oral hypoglycemic drugs and insulin analogues …

The interplay of various body systems, encompassing those that govern cardiovascular and
metabolic functions, has evolved alongside the development of multicellular organisms. This …

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with
various phenotypes, and obesity is one of the most common and clinically relevant …

Incretin-based drugs may represent a milestone in the treatment of obesity in HFpEF.
Elucidating the contribution of weight loss in the overall benefit observed with these drugs is …